Subject Expert Committee (SEC) meets to consider Emergency Use Authorisation request from Pfizer, SII and Bharat Biotech

The Subject Expert Committee (SEC) in the Central Drugs Standard Control Organisation (CDSCO) to consider the Emergency Use Authorisation (EUA) request of Pfizer, Serum Institute of India (SII) and Bharat Biotech Pvt. Ltd.

Further time was requested on behalf of Pfizer. The additional data and information presented by SII and Bharat Biotech Pvt. Ltd. was perused and analysed by the SEC.

The analysis of the additional data and information is going on. SEC will convene again on 01-01- 2021.

Ministry of Health and Family Welfare

[Press Release dt. 30-12-2020]

[Source: PIB]

Join the discussion

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.